Anesthesiology
Potent opioids, modest antidote: limits of standard-dose intranasal naloxone
Clinical Takeaway: After intranasal naloxone, continue close monitoring and be prepared to redose or escalate care—even if ventilation appears to recover.
In the fentanyl era, apparent reversal of breathing may mask ongoing hypercapnia and respiratory instability.
A prospective crossover study examined how well a single 4-mg dose of intranasal naloxone (Narcan) reverses opioid-induced respiratory depression from fentanyl and sufentanil in opioid-naive volunteers and people who self-reported daily opioid use.
Thirty participants (12 opioid-naive; 18 daily users, median 291 morphine milligram equivalents/day) received controlled opioid infusions titrated to reduce minute ventilation by 30% to 40%. Naloxone was administered at steady-state respiratory depression, with recovery of ventilation and end-tidal CO₂ as primary endpoints.
Naloxone rapidly restored minute ventilation in all participants—typically within 2 to 4 minutes—regardless of opioid exposure or user status. However, normalization of end-tidal CO₂ was significantly slower, taking 11 to 17 minutes on average, and was incomplete in some cases. During exposure to the higher–μ-opioid-affinity drug sufentanil, full CO₂ recovery occurred in only 8 opioid-naive participants and 10 daily opioid users.
Pharmacodynamic modeling showed near-immediate effects on ventilation (effect-site half-life 0–1 min), contrasted with delayed CO₂ clearance (half-life 2–11 min). Seven daily opioid users discontinued one arm due to withdrawal symptoms.
“Our study shows that current doses of naloxone may not be sufficient to reverse overdoses caused by newer synthetic opioids,” lead author Maarten A. van Lemmen, PhD, said, underscoring the need for vigilance after initial reversal.
Source: van Lemmen MA, et al. (2026, May). Anesthesiology. Intranasal Naloxone Reversal of Opioid-induced Respiratory Depression in Opioid-naive Individuals and Self-reported Daily Opioid Users